Evotec AG has announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders.
Epidarex Capital, EMBL Ventures and Gimv participated together with Evotec in the EUR 14 m ($ 15.75 m) Series A round of Topas Therapeutics GmbH. Evotec will remain the largest shareholder after the financing round.
The new company, Topas Therapeutics GmbH ("Topas"), aims to build a unique pipeline of clinical-stage development projects to treat autoimmune diseases. The proceeds of the Series A funding enable Topas to expand and accelerate its proprietary liver-based tolerance induction platform and to progress with its own product development efforts in multiple autoimmune and inflammatory indications including multiple sclerosis into clinical proof-of-concept ("POC") stage.
Dr Timm Jessen, Chief Executive Officer of Topas, stated: "We are delighted to engage with such a strong and experienced consortium of investors who share with us the excellence and commercial potential of this unique mode to induce antigen-specific tolerance in autoimmune diseases and beyond."
Dr Werner Lanthaler, Chief Executive Officer of Evotec and interim Chairman of the Supervisory Board of Topas, commented: "We are very excited by Topas' unique product-platform technology, which has significant breakthrough potential. The company formation of Topas is the first example of an acceleration of our business model representing an optimal risk-reward profile up to clinical proof-of-concept stage for our shareholders in selected fields of high strategic medical relevance."
Peter Finan PhD, Partner at Epidarex Capital, commented: "Topas Therapeutics' unique approach to tolerance has the potential to lead to transformative medicines in diseases of high unmet medical need. We are delighted to have led the financing with such strong co-investors and we look forward to working closely with the Topas team to realise this potential."